Bellevue Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.2M Sell
33,932
-71
-0.2% -$72K 0.74% 38
2025
Q4
$36.5M Sell
34,003
-6,511
-16% -$6.23M 0.69% 35
2025
Q3
$30.9M Sell
40,514
-406
-1% -$302K 0.64% 37
2025
Q2
$31.9M Sell
40,920
-2,727
-6% -$2.12M 0.7% 37
2025
Q1
$36M Sell
43,647
-1,818
-4% -$1.51M 0.81% 30
2024
Q4
$35.1M Buy
45,465
+1,219
+3% +$1.01M 0.68% 34
2024
Q3
$39.2M Sell
44,246
-5,428
-11% -$4.88M 0.64% 43
2024
Q2
$45M Sell
49,674
-8,291
-14% -$6.63M 0.73% 34
2024
Q1
$45.1M Buy
57,965
+1,753
+3% +$1.25M 0.69% 46
2023
Q4
$32.8M Sell
56,212
-25,329
-31% -$14.8M 0.5% 59
2023
Q3
$43.8M Sell
81,541
-13,614
-14% -$7.02M 0.71% 43
2023
Q2
$44.6M Buy
95,155
+84,391
+784% +$35.4M 0.64% 52
2023
Q1
$3.7M Sell
10,764
-291
-3% -$98.1K 0.05% 109
2022
Q4
$4.04M Buy
11,055
+1,565
+16% +$555K 0.05% 113
2022
Q3
$3.07M Buy
9,490
+8,521
+879% +$2.7M 0.04% 115
2022
Q2
$314K Buy
+969
New +$291K ﹤0.01% 152
2022
Q1
Sell
-7,552
Closed -$2.09M 190
2021
Q4
$2.09M Buy
+7,552
New +$1.91M 0.02% 146
2018
Q1
Sell
-241,262
Closed -$20.4M 130
2017
Q4
$20.4M Hold
241,262
2.13% 13
2017
Q3
$20.6M Buy
241,262
+60,189
+33% +$4.94M 2.16% 11
2017
Q2
$14.9M Buy
181,073
+49,673
+38% +$4.05M 1.76% 16
2017
Q1
$11.1M Buy
131,400
+96,400
+275% +$7.72M 1.47% 26
2016
Q4
$2.57M Hold
35,000
0.53% 50
2016
Q3
$2.81M Hold
35,000
0.51% 57
2016
Q2
$2.76M Hold
35,000
0.52% 57
2016
Q1
$2.52M Buy
+35,000
New +$2.65M 0.46% 70

Other funds holding LLY

Bellevue Group's LLY Position: Q1 2026 in Review

Bellevue Group reduced its Eli Lilly (LLY) stake by 0.21% in Q1 2026, selling an estimated $72K and leaving 33,932 shares worth $31.2M. The position accounts for 0.74% of the portfolio, ranked #38.

Bellevue Group first reported a position in LLY in Q1 2016 and has held it in 25 quarters since. The position peaked at $45.1M in Q1 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bellevue Group held 33,932 shares of Eli Lilly worth $31.2M as of Q1 2026.
  • Bellevue Group sold 71 Eli Lilly shares in Q1 2026, an estimated $72K.
  • Eli Lilly made up 0.74% of Bellevue Group's portfolio in Q1 2026, its #38 holding.
  • Bellevue Group first reported a position in Eli Lilly in Q1 2016 and has held it in 25 quarters since.
  • Bellevue Group's Eli Lilly position peaked at $45.1M in Q1 2024.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.